Company Overview
About Chai Discovery
Chai Discovery is an AI biotech founded in 2023 by Jack Dent, Jacques Boitreaud, Matthew McPartlon, and Joshua Meier (from OpenAI, Meta FAIR, Stripe, Google X), headquartered in San Francisco. Builds AI foundation models to predict and design biochemical molecules.
Business Model & Competitive Advantage
December 2025: $130M Series B co-led by Oak HC/FT and General Catalyst at $1.3B (unicorn). Following $70M Series A (August 2025). Total $225M+ from OpenAI, Thrive Capital, Menlo Ventures, Dimension.
Competitive Landscape 2025–2026
Chai 2: first zero-shot generative platform achieving double-digit success rates in de novo antibody design — 100x improvement over previous methods. Eli Lilly partnership. Building a "computer-aided design suite" for molecules.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Chai Discovery is an established challenger with significant market presence and competitive offerings in Healthcare Tech.
Enterprise Scale
With $1300M in revenue, Chai Discovery operates at enterprise scale with proven market validation.
Frequently Asked Questions
Compare Chai Discovery with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Start Comparison →Claim This Profile
Are you from Chai Discovery? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Chai Discovery Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Chai Discovery vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →